Atomwise
Atomwise raises $123M
Artificial intelligence-based drug discovery portfolio company Atomwise has closed $123 million in a Series B funding round.
Atomwise enters into an evaluation agreement with Pfizer
Atomwise has entered into an evaluation agreement with Pfizer, in which the drug giant will evaluate Atomwise’s platform to identify potential drug candidates.